logo
EXCLUSIVE Inside the underground bunkers where cancer kids are shielded from the Iranian missiles

EXCLUSIVE Inside the underground bunkers where cancer kids are shielded from the Iranian missiles

Daily Mail​25-06-2025
In the middle of a warm summer night, as explosions boomed and sirens wailed overhead, a brave operation unfolded. Gravely ill children, some hooked up to life-saving machines, were rushed to underground bunkers.
The corridors of Schneider Children's Medical Center in Petah Tikvah, Israel, were brimming as nurses and doctors moved with great urgency in a race to protect their patients.
In this region, such scenes are tragically familiar. Witnessing it up close in this children's hospital, though, was both extraordinary and heart wrenching - a Herculean effort to shield the most vulnerable from the violence above.
'My daughter has leukemia and she is more afraid of the missiles than the illness,' says Taufick Zangaria, whose nine-year-old daughter, Joory, is among the patients.
The little girl, whose name is a type of flower in Arabic, is two months into her treatment which consists of chemotherapy. As if that is not enough for her to contend with, today she - alongside hundreds of others - are being hurried into shelters underneath the hospital as the latest salvo of missiles are fired from Iran.
Too many innocent children have been killed in this awful conflict. In Gaza, where Hamas blocks civilians from entering its extensive 500km underground tunnel network, child patients have nowhere to shelter.
Israel, a country always under attack by enemies that surround it, has invested billions in building the best air defence system in the world. It is this, alongside precise early warning systems, plentiful bomb shelters and organised drills, that have largely protected them until now.
But the sheer ferocity of Iran's latest bombardment is testing even these defences. Some 29 people have been killed to date.
The largest ballistic missile attack in history took place on October 1, 2024 when the Iranian Revolutionary Guard launched around 200 at Israel. Now the Iranians have doubled that over the course of just a few days. Israelis will tell you this is a whole different level of attack. For reference, Vladimir Putin fires around 50 ballistic missiles per month in Ukraine. Were it not for the Iron Dome, it does not bear thinking about.
Last week the Iranian regime fired a cluster bomb warhead missile at Soroka Medical Center in southern Israel, injuring about 80 people. Hospital staff say that it was so forceful the blast sent them flying backwards. Doctors claim many more would have suffered a worse fate had they not evacuated everyone to the bunkers in time.
Mr Zangaria says his daughter has learned how to cope with life-saving treatment in a war zone.
'My little girl is so brave, but missiles have become a way of life for children,' he laments. 'It doesn't matter if they are Muslims, Christians or Jewish kids, we are all a target. The hospital is incredible, all of us working together to keep the kids safe and cancer-free, all denominations.
'We live in the north of Israel called Tuba-Zangariyye which is a Muslim village, 40 minutes from the Syrian border, and we see rockets flying overhead from Iran. It's quite a drive from the hospital and my wife and six-year-old son stay there while Joory is undergoing treatment. Sometimes she cries for her mother and there is nothing we can do, but luckily we are in safe hands here and that reassures her mother.
'The war and my daughter's illness shows us the kindness of people of Israel from all walks of life. The hospital is outstanding the way they care for my child. Our country helps with everything, the social system is incredible, we get everything we need from the state for Joory.'
In this hospital patients would normally have 90 seconds to get to a shelter - or stairwell, as has been the case during Hamas, Houthi or Hezbollah rockets and missiles - but this time not one day has gone by without an Iranian missile.
Doctor Joanne Yacobovich, who is the head of the Hematology Oncology department, says doctors have many other worries.
'The worst fear for any doctor is that there is a direct hit on the building, especially after what happened at Soroka Medical Center... it's on everyone's mind. What happens if the building gets hit? If the building collapses how do we get patients out? What happens when there is a siren and we are in the middle of a procedure and a patient is under anesthesia and you cannot move them?
'Everyone has been caring 24 hours a day, people just came in to help move the hospital without even being called. When Soroka was hit we offered to bring patients to us. We are doing all that we can do to get the children healthy'.
'Ten minutes after the siren went off I told everyone to start moving the children,' says the CEO of the hospital Dr Efrat Bron-Harlev. 'So we started moving the entire hospital at 3am and by 8am every patient was in the bunkers.
'I never imagined it would be like this. I told everyone ten minutes after the alarm rang to start moving. We were very scared yet all the teams left their beds at home, under an attack, to come in and make it happen. All the kids on machines and in their beds were moved - no one was left behind.
'For me one of the most frightening things to move was the bone marrow department. These patients must be kept in isolation, away from germs. We have done our best to move them downstairs, but it's thanks to the teams here who made that happen.
'The only thing we had in mind was keeping the kids safe from the missiles, and they tell me they feel safe'.
Noa Asban's mum Hila said that on the night of the attack, her sister was sleeping with her daughter as she was home with her four other kids. As often is the case with families, they take it in turns to be with the child receiving treatment, which can mean a long stay. That night her mother tells me she reassured her that Noa was in the best of hands and was gently wheeled downstairs in a calm manner.
Hila says Noa, age four and who has leukaemia, is too young to understand the war - but often gives strength to her older brother, age eleven, who is scared of missiles, she tells the Mail.
'There are a lot of us downstairs but it's clean and organised. You think people would be stressed but we are not, the medical team is incredible. The girls that volunteer to be with kids as their national service are angels... they play with the kids and help the families.'
The oncology ward bunker is quite stuffy with many patients in a large room separated by curtains. Yet the staff are full of smiles and a clown is walking around the wards.
Hila says: 'Bat Sheruts' young girls that choose to volunteer instead of serving in the mandatory army adorn the corridors with arts and crafts for the kids. If it wasn't for the windowless environment one may forget the country was at war.'
'The day the doctors told me Joory had leukaemia I cried my heart out,' says Mr Zangaria. 'She's a miracle girl, she came after miscarriages and difficulties. She's already proven herself, the doctors are all crazy about her. I know she will come out of this stronger.'
After 12 days of conflict a ceasefire has been agreed and the children made their way back up again this morning in the same manner they went below ground. As they look forward to the future and some kind of normality, they're hoping that the ceasefire holds.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Type 2 diabetes patients set for major shake-up in care
Type 2 diabetes patients set for major shake-up in care

The Independent

time43 minutes ago

  • The Independent

Type 2 diabetes patients set for major shake-up in care

People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'

More weight-loss drugs offered in type 2 diabetes care shake-up
More weight-loss drugs offered in type 2 diabetes care shake-up

BBC News

timean hour ago

  • BBC News

More weight-loss drugs offered in type 2 diabetes care shake-up

Treatment for millions of people with type 2 diabetes should be more personalised, with greater access to newer medicines, including weight-loss drugs, the healthcare assessment body for England, Wales and Northern Ireland has calls the move "the biggest shake-up" in type 2 diabetes care in a more people the new drugs will prevent complications such as heart disease, strokes and kidney damage, reduce costs to the NHS and potentially save lives, the National Institute for Health and Care Excellence (NICE) says. Around 4.6 million people in the UK are diagnosed with diabetes - of these 90% have type 2, with another 1.3 million likely to be undiagnosed. Having type 2 diabetes means there is too much glucose or sugar in the blood. This makes strokes, heart attacks, heart failure and other health conditions much more of a risk. It is now so common that 10% of the NHS budget goes towards treating which produces guidance for the NHS on how to give patients the best care, recommends a move away from a "one size fits all" approach and towards more personalised is calling for newer diabetes medicines called SGLT-2 inhibitors, which protect the heart and kidneys as well as lowering blood sugar levels, to become the first-choice treatment for all diabetes patients. Around 2.3 million people will be eligible for these 22,000 lives could be saved if 90% of all diabetes patients were prescribed them, NICE says, but access is not equal across the UK. There is evidence that women, older people and black people are less likely to be prescribed them."There is some urgency to find ways to increase the uptake of SGLT-2 inhibitors because if we were to achieve perfect uptake, the nation would be significantly healthier," said Dr Waqaar Shah, chair of the guideline one in five people with type 2 diabetes and cardiovascular disease are currently prescribed the the tablets to more people would particularly benefit those living in poorer areas and ethnic minorities, NICE says. Under the guidance, which is still at a draft stage and needs to go through a consultation, around 750,000 more people with type 2 diabetes will be offered GLP-1 agonists such as semaglutide and liraglutide, which have become very popular as the drugs contained in weight-loss with cardiovascular disease and some who develop type 2 before they are 40 are the groups recommended to be offered drugs can be used both to lower blood sugar levels and to support some people with weight Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the updated guidance was "a significant evolution" in type 2 diabetes treatment which could help prevent heart attacks, strokes and other serious complications before they happen."This guidance means more people will be offered medicines, where it is right to do so, to reduce their future risk of ill health," he guidelines are part of a long-term plan by the NHS in England to reduce health inequalities and focus on preventing ill health in the first charity Diabetes UK said the announcement propelled type 2 diabetes treatments "into the 21st century"."These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes," said Douglas Twenefour, head of clinical at the charity.

Diabetes patients could be offered weight loss jabs sooner in major shake-up
Diabetes patients could be offered weight loss jabs sooner in major shake-up

The Independent

time2 hours ago

  • The Independent

Diabetes patients could be offered weight loss jabs sooner in major shake-up

People with type 2 diabetes in England could be offered treatments, including weight loss jabs, sooner in the biggest shake-up of care in a decade. New draft guidance from the National Institute for Health and Care Excellence (Nice) recommends a shift from a one-size-fits-all approach of starting everyone on the same medication to more personalised care that aims to prevent complications like heart failure and heart attacks. Newer type 2 diabetes drugs, known as SGLT-2 inhibitors, would be made a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as control blood sugar, Nice said. It is estimated that the change could save almost 22,000 lives once uptake reaches 90 per cent of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store